留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

糠酸氟替卡松/维兰特罗复方剂治疗哮喘疗效与耐受性的Meta分析

林莉莉,  姚囡囡,  吴珏,  刘志宏,  宋洪涛

downloadPDF
文章导航 > 药学实践与服务  > 2019 >  37(5): 473-480
林莉莉, 姚囡囡, 吴珏, 刘志宏, 宋洪涛. 糠酸氟替卡松/维兰特罗复方剂治疗哮喘疗效与耐受性的Meta分析[J]. 药学实践与服务, 2019, 37(5): 473-480. doi: 10.3969/j.issn.1006-0111.2019.05.018
引用本文: 林莉莉, 姚囡囡, 吴珏, 刘志宏, 宋洪涛. 糠酸氟替卡松/维兰特罗复方剂治疗哮喘疗效与耐受性的Meta分析[J]. 药学实践与服务, 2019, 37(5): 473-480. doi: 10.3969/j.issn.1006-0111.2019.05.018
shu
LIN Lili, YAO Nannan, WU Jue, LIU Zhihong, SONG Hongtao. Efficacy and safety of fluticasone furoate/vilanterol in patients with asthma: a systematic review by Meta-analysis[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(5): 473-480. doi: 10.3969/j.issn.1006-0111.2019.05.018
Citation: LIN Lili, YAO Nannan, WU Jue, LIU Zhihong, SONG Hongtao. Efficacy and safety of fluticasone furoate/vilanterol in patients with asthma: a systematic review by Meta-analysis[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(5): 473-480. doi: 10.3969/j.issn.1006-0111.2019.05.018
shu

糠酸氟替卡松/维兰特罗复方剂治疗哮喘疗效与耐受性的Meta分析

doi: 10.3969/j.issn.1006-0111.2019.05.018
  • 1.

    沈阳药科大学生命科学与生物制药学院, 辽宁 沈阳 110016

  • 2.

    中国人民解放军联勤保障部队第九○○医院药学科, 福建 福州 350025

Efficacy and safety of fluticasone furoate/vilanterol in patients with asthma: a systematic review by Meta-analysis

  • 1.

    Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China

  • 2.

    Department of Pharmacy, No. 900 Hospital of Joint Service Support Force, Fuzhou 350025, China

  • 摘要: 目的 比较糠酸氟替卡松/维兰特罗复方剂（FF/VI）与吸入型糖皮质激素单药或联合长效β2受体激动剂治疗哮喘患者的疗效与耐受性差异。 方法 计算机检索CNKI、PubMed、Embase、Cochrane Library等数据库，纳入随机对照试验，采用Cochrane系统评价方法进行评价。 结果 共纳入10个研究，共9 811例患者。在疗效上，FF/VI组与对照组相比，提高患者的1秒用力呼气量谷值[WMD=0.09，95% CI（0.05，0.13），P=0.000]和哮喘控制测试评分[WMD=0.63，95% CI（0.24，1.03），P=0.002]。在耐受性方面，FF/VI组与对照组相比不增加患者发生与治疗相关不良反应事件风险[RR=1.15，95% CI（0.98，1.36），P=0.000]。 结论 用FF/VI治疗哮喘在疗效方面具有优势，且具有良好的耐受性。其每日1次的用药频次可提高患者依从性，值得推荐使用。
    Abstract: Objective To evaluate the efficacy and safety of once-daily fluticasone furoate/vilanterol compared with ICS alone or twice-daily ICS/LABA formulations in patients with asthma. Methods Systematic search was performed for randomized controlled trials in the CNKI,PubMed,Embase and Cochrane Library. Results 10 citations contained 9 811 patients with asthma met the selection criteria. In terms of efficacy,compared with the control group,the patient's trough forced expiratory volume in one second[WMD=0.09,95% Cl(0.05,0.13) P=0.000] and asthma control Test score[WMD=0.63,95% CI(0.24,1.03),P=0.002] were increased in the FF/VI group. In terms of safety,the risk of adverse reaction events associated with treatment in patients was not increased in the FF/VI group compared to the control group[RR=1.15,95% CI(0.98,1.36),P=0.000]. Conclusion FF/VI had advantages and better tolerance in treating asthma patients. It is recommended to be used for its once-daily use of the frequency,which was the advantage of improving patient adherence.
  • [1] 林燕萍.支气管哮喘防治指南(支气管哮喘的定义、诊断、治疗和管理方案)[C].中国中西医结合变态反应学术会议.2009.
    [2] BATEMAN E D,HURD S S,BARNES P J,et al. Global strategy for asthma management and prevention:GINA executive summary[J].Eur Respir J,2008,31(1):143-178.
    [3] BLAIS L,SUISSA S,BOIVIN J F,et al. First treatment with inhaled corticosteroids and the prevention of admissions to hospital for asthma[J].Thorax,1998,53(12):1025-1029.
    [4] SHIMODA T,OBASE Y,KISHIKAWA R,et al. Impact of inhaled corticosteroid treatment on 15-year longitudinal respiratory function changes in adult patients with bronchial asthma[J].Int Arch Allergy Immunol,2013,162(4):323-329.
    [5] SUISSA S,ERNST P,BENAYOUN S,et al. Low-dose inhaled corticosteroids and the prevention of death from asthma[J].N Engl J Med,2000,343(5):332-336.
    [6] TOY E L,BEAULIEU N U,MCHALE J M,et al. Treatment of COPD:Relationships between daily dosing frequency,adherence,resource use,and costs[J].Respir Med,2011,105(3):435-441.
    [7] GAMBLE J,STEVENSON M,MCCLEAN E,et al. The prevalence of nonadherence in difficult asthma[J]. Am J Respir Crit Care Med,2009,180(9):817-822.
    [8] BERNSTEIN D I,BATEMAN E D,WOODCOCK A,et al. Fluticasone furoate (FF)/vilanterol (100/25mcg or 200/25mcg) or FF (100mcg) in persistent asthma[J]. J Asthma,2015,52(10):1073-1083.
    [9] DEVILLIER P,HUMBERT M,BOYE A,et al. Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β2-agonists (ICS/LABA) in patients with uncontrolled asthma:An open-label,randomized,controlled trial[J].Respir Med,2018,141:111-120.
    [10] JACQUES L,BAKERLY N D,NEW J P,et al. Effectiveness of fluticasone furoate/vilanterol versus fluticasone propionate/salmeterol on asthma control in the Salford Lung Study[J].J Asthma,2018:1-10.
    [11] 张菲,江兵,缪李丽.糠酸氟替卡松治疗支气管哮喘疗效及安全性的系统评价[J].中国循证医学杂志,2017,17(1):33-39.
    [12] MOHER D,LIBERATI A,TETZLAFF J,et al. Preferred reporting items for systematic reviews and meta-analyses:The PRISMA statement[J].Int J Surg,2010,8(5):336-341.
    [13] BUSSE W W,O'BYRNE P M,BLEECKER E R,et al. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β2-agonist vilanterol administered once daily for 52 weeks in patients ≥ 12 years old with asthma:a randomised trial[J].Thorax,2013,68(6):513-520.
    [14] WOODCOCK A,BLEECKER E R,LOTVALL J,et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma:a randomized trial[J].Chest,2013,144(4):1222-1229.
    [15] O'BYRNE P M,BLEECKER E R,BATEMAN E D,et al. Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma[J].Eur Respir J,2014,43(3):773-782.
    [16] BATEMAN E D,O'BYRNE P M,BUSSE W W,et al. Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone[J].Thorax,2014,69(4):312-319.
    [17] BLEECKER E R,LOTVALL J,O'BYRNE P M,et al. Fluticasone furoate-vilanterol 100-25 mcg compared with fluticasone furoate 100 mcg in asthma:a randomized trial[J].J Allergy Clin Immunol Pract,2014,2(5):553-561.
    [18] LIN J,KANG J,LEE S H,et al. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients:A randomized trial[J].Respir Med,2015,109(1):44-53.
    [19] BERNSTEIN D I,BATEMAN E D,WOODCOCK A,et al. Fluticasone furoate (FF)/vilanterol (100/25mcg or 200/25mcg) or FF (100mcg) in persistent asthma[J]. J Asthma,2015,52(10):1073-1083.
    [20] GROSS A S,GOLDFRAD C,HOZAWA S,et al. Ethnic sensitivity assessment of fluticasone furoate/vilanterol in East Asian asthma patients from randomized double-blind multicentre Phase Ⅱb/Ⅲ trials[J]. Bmc Pulm Med,2015,15(1).
    [21] DEVILLIER P,HUMBERT M,BOYE A,et al. Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β2-agonists (ICS/LABA) in patients with uncontrolled asthma:An open-label,randomized,controlled trial[J].Respir Med,2018,141:111-120.
    [22] BIGGADIKE K. Fluticasone furoate/fluticasone propionate-different drugs with different properties[J].Clin Respir J,2011,5(3):183-184.
    [23] BIGGADIKE K,BLEDSOE R K,HASSELL A M,et al. X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocoricoid receptor ligand binding domain[J].J Med Chem,2008,51(12):3349-3352.
    [24] SALTER M,BIGGADIKE K,MATTHEWS J L,et al. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease[J].Am J Physiol-Lung C,2007,293(3):L660-L667.
    [25] VALOTIS A,HOGGER P. Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate[J].Respir Res,2007,8:54.
    [26] ALLEN A,BAREILLE P J,ROUSELL V M. Fluticasone furoate,a novel inhaled corticosteroid,demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate[J].Clin Pharmacokinet,2013,52(1):37-42.
    [27] ROSSIOS C,TO Y,TO M,et al. Long-acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cells[J].Eur J Pharmacol,2011,670(1):244-251.
    [28] PROCOPIOU P A,BARRETT V J,BEVAN N J,et al. Synthesis and structure activity relationships of long-acting β2 adrenergic receptor agonists incorporating metabolic inactivation:an antedrug approach[J].J Med Chem,2010,53(11):4522-4530.
  • [1] 黄韵, 张正银, 金英, 郑怡菁, 李铁军, 孙莉莉.  耐碳青霉烯类肺炎克雷伯菌及大肠埃希菌临床分离株耐药性及耐药基因分析 . 药学实践与服务, 2024, 42(10): 439-444. doi: 10.12206/j.issn.2097-2024.202309059
    [2] 刘丽艳, 余小翠, 孙传铎.  纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(10): 451-456. doi: 10.12206/j.issn.2097-2024.202310044
    [3] 张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英.  二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 319-324. doi: 10.12206/j.issn.2097-2024.202308062
    [4] 史生辉, 石飞, 雷琼, 王亚峰, 吴雪花.  青藏高原肺结核合并念珠菌感染患者的病原菌分布特点及耐药率分析 . 药学实践与服务, 2024, 42(6): 260-262, 272. doi: 10.12206/j.issn.2097-2024.202304014
    [5] 王鹏, 陈顺, 赵逸, 高守红, 王志鹏.  卡培他滨致小鼠手足综合征模型的建立及评价 . 药学实践与服务, 2024, 42(9): 385-388, 398. doi: 10.12206/j.issn.2097-2024.202308045
    [6] 桂明珠, 李静, 李志玲.  儿童伏立康唑的血药浓度与CYP2C19、CYP2C9和CYP3A5基因多态性的相关性研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202402020
    [7] 戴菲菲, 傅翔, 陈琼年, 俞苏纯.  上海某二级医院革兰阴性菌流行特征的回顾性分析 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202305005
    [8] 刘依秦, 王超群, 邱娇娜.  胆宁片预处理在糖尿病患者结肠镜检查前的应用效果分析 . 药学实践与服务, 2024, 42(9): 407-410. doi: 10.12206/j.issn.2097-2024.202407037
    [9] 张林晨, 张小琴, 张俊平.  山楂酸药理作用的研究进展 . 药学实践与服务, 2024, 42(5): 185-189. doi: 10.12206/j.issn.2097-2024.202307052
    [10] 凯丽比努尔·奥布力艾散, 李倩, 谢志, 贾文彦, 尹东锋.  星点设计-效应面法优化仑伐替尼混合胶束的制备工艺 . 药学实践与服务, 2024, 42(11): 495-502. doi: 10.12206/j.issn.2097-2024.202403019
    [11] 瞿文君, 白若楠, 崔力, 周琰.  基于联合库存的公立医院多院区药品采购模式分析 . 药学实践与服务, 2024, 42(7): 315-318. doi: 10.12206/j.issn.2097-2024.202401002
    [12] 宋红卫, 王燕, 方铭, 马云鹏, 钟超, 徐一新, 徐峰, 周婷.  2021−2023年我院药品不良反应的特点分析 . 药学实践与服务, 2024, 42(): 1-6. doi: 10.12206/j.issn.2097-2024.202404041
    [13] 张晶晶, 索丽娜, 郑兆红.  89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
    [14] 尹小娟, 台力丽, 肖俊峰, 季波.  铜绿假单胞菌合并按蚊伊丽莎白菌肺部感染的病例分析 . 药学实践与服务, 2024, 42(5): 223-226. doi: 10.12206/j.issn.2097-2024.202310042
    [15] 姚瑞阳, 于海征, 李耀盺, 张磊.  丹参FBXL 基因家族的鉴定和表达模式分析 . 药学实践与服务, 2024, 42(11): 461-470. doi: 10.12206/j.issn.2097-2024.202407034
    [16] 张岩, 李炎君, 刘家荟, 邓娇, 原苑, 张敬一.  药物性肝损伤不良反应分析 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202404034
    [17] 毛智毅, 王筱燕, 陈晓颖, 汤逸斐.  度拉糖肽联合二甲双胍对肥胖型2型糖尿病患者机体代谢、体脂成分及血清脂肪因子的影响 . 药学实践与服务, 2024, 42(7): 305-309. doi: 10.12206/j.issn.2097-2024.202305032
    [18] 王耀振, 徐灿, 吕顺莉, 田泾, 张东炜.  钾离子竞争性酸阻滞剂的药学特征研究进展 . 药学实践与服务, 2024, 42(7): 278-284. doi: 10.12206/j.issn.2097-2024.202306040
    [19] 崔晓林, 付晓菲, 杜艳红, 刘娟, 朱茜, 刘子祺.  临床药师参与吉瑞替尼致QTc间期延长的病例分析 . 药学实践与服务, 2024, 42(6): 263-266. doi: 10.12206/j.issn.2097-2024.202309050
    [20] 陈春娟, 郑志新, 李骊.  平喘方联合孟鲁司特钠治疗儿童支气管哮喘患者的临床疗效观察 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202405035
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  3660
  • HTML全文浏览量:  495
  • PDF下载量:  328
  • 被引次数: 0
出版历程
  • 收稿日期:  2018-10-10
  • 修回日期:  2018-12-29

糠酸氟替卡松/维兰特罗复方剂治疗哮喘疗效与耐受性的Meta分析

doi: 10.3969/j.issn.1006-0111.2019.05.018
  • 1. 沈阳药科大学生命科学与生物制药学院, 辽宁 沈阳 110016
  • 2. 中国人民解放军联勤保障部队第九○○医院药学科, 福建 福州 350025
  • 收稿日期: 2018-10-10
  • 修回日期: 2018-12-29

摘要: 目的 比较糠酸氟替卡松/维兰特罗复方剂（FF/VI）与吸入型糖皮质激素单药或联合长效β2受体激动剂治疗哮喘患者的疗效与耐受性差异。 方法 计算机检索CNKI、PubMed、Embase、Cochrane Library等数据库，纳入随机对照试验，采用Cochrane系统评价方法进行评价。 结果 共纳入10个研究，共9 811例患者。在疗效上，FF/VI组与对照组相比，提高患者的1秒用力呼气量谷值[WMD=0.09，95% CI（0.05，0.13），P=0.000]和哮喘控制测试评分[WMD=0.63，95% CI（0.24，1.03），P=0.002]。在耐受性方面，FF/VI组与对照组相比不增加患者发生与治疗相关不良反应事件风险[RR=1.15，95% CI（0.98，1.36），P=0.000]。 结论 用FF/VI治疗哮喘在疗效方面具有优势，且具有良好的耐受性。其每日1次的用药频次可提高患者依从性，值得推荐使用。

English Abstract

林莉莉, 姚囡囡, 吴珏, 刘志宏, 宋洪涛. 糠酸氟替卡松/维兰特罗复方剂治疗哮喘疗效与耐受性的Meta分析[J]. 药学实践与服务, 2019, 37(5): 473-480. doi: 10.3969/j.issn.1006-0111.2019.05.018
引用本文: 林莉莉, 姚囡囡, 吴珏, 刘志宏, 宋洪涛. 糠酸氟替卡松/维兰特罗复方剂治疗哮喘疗效与耐受性的Meta分析[J]. 药学实践与服务, 2019, 37(5): 473-480. doi: 10.3969/j.issn.1006-0111.2019.05.018
shu
LIN Lili, YAO Nannan, WU Jue, LIU Zhihong, SONG Hongtao. Efficacy and safety of fluticasone furoate/vilanterol in patients with asthma: a systematic review by Meta-analysis[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(5): 473-480. doi: 10.3969/j.issn.1006-0111.2019.05.018
Citation: LIN Lili, YAO Nannan, WU Jue, LIU Zhihong, SONG Hongtao. Efficacy and safety of fluticasone furoate/vilanterol in patients with asthma: a systematic review by Meta-analysis[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(5): 473-480. doi: 10.3969/j.issn.1006-0111.2019.05.018
shu

    全文HTML

参考文献 (28)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: [email protected]

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计